Sequana Medical - Green light to go on with MOJAVE
Sequana Medical announced that following the review of the safety data from the 3-patients non-randomized cohort, the independent Data Safety Monitoring Board approved the enrollment of the entire 30-patients randomized cohort in the MOJAVE study (heart failure program). Interim results foreseen in H2.Follow-up data from the non-randomized cohort confirms the benefits of the DSR therapy with DSR 2.0.Given the good safety profile of DSR 2.0, we expected this approval. This is a positive news but no impact on our estimates. Given the early development stage of the program with only a limited number of patients enrolled so far and theSequana Medical NV. Sequana Medical NV is a Belgium-based company, which manufactures medical devices. The Company focuses mainly on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical NV provides alfapump, which is an implantable, programmable, wireless-charged and battery-powered system that is CE-marking for the management of refractory ascites due to liver cirrhosis and malignant ascites. Over 650 alfapump systems have been implanted. Apart from the Alfapump, the Company also aims to develop a direct sodium removal (DSR) therapy, which is a propriety approach to the treatment of volume overload in heart failure.
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.